A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics

Psychopharmacology

Volumn 231, Issue 24, 2014, Pages 4703-4710

  Gilca, Marilena ^a,b   Piriu, Gabriela ^a,c   Gaman, Laura ^a,b   Delia, Corina ^d   Iosif, Liviu ^b   Atanasiu, Valeriu ^a   Stoian, Irina ^a,b  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b R D Irist Labmed SRL   (Romania)

^c Department of Psychiatry Sapoca Psychiatric Hospital   (Romania)

^d Institute for Mother and Child Care Alfred Rusescu   (Romania)

Author keywords

Antioxidant; Arylesterase; Atypical antipsychotic; PON; TEAC

Indexed keywords

ARYLDIALKYLPHOSPHATASE; CLOZAPINE; LIPID; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; BLOOD; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; RISK FACTOR; SCHIZOPHRENIA; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; ARYLDIALKYLPHOSPHATASE; CARDIOVASCULAR DISEASES; CLOZAPINE; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS; RISPERIDONE; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 84937868087     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3624-0     Document Type: Article

References (42)

1. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP et al (1999a) The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 60:215-220
2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al (1999b) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696
3. Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, Daumit GL et al (2009) Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am J Prev Med 36:341-350
4. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN (1999) Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 19:330-335
5. Baig MR, Navaira E, Escamilla MA, Raventos H, Walss-Bass C (2010) Clozapine treatment causes oxidation of proteins involved in energy metabolism in lymphoblastoid cells: a possible mechanism for antipsychotic-induced metabolic alterations. J Psychiatr Pract 16(5):325-333
6. Baptista T, ElFakih Y, Uzcategui E, Sandia I, Talamo E, Araujo de Baptist et al (2008) Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 22:477-495
7. Dalla Libera A, Scutari G, Boscolo R, Rigobello MP, Bindoli A (1998) Antioxidant properties of clozapine and related neuroleptics. Free Radic Res 29:151-157
8. Durrington PN, Mackness B, Mackness MI (2001) Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21:473-480
9. Esfahani A, Wong JMW, Truan J, Villa CR, Mirrahimi A, Srichaikul K et al (2011) Health effects of mixed fruit and vegetable concentrates: a systematic review of the clinical interventions. J Am Coll Nutr 30:285-294
10. Fehsel K, Loeffler S, Krieger K, Henning U, Agelink M, Kolb-Bachofen V et al (2005) Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients. J Clin Psychopharmacol 25(5):419-426
11. First MB, Pincus HA (1999) Definitions of schizophrenia. Br J Psychiatry 174:273
12. Gaidukov L, Tawfik DS (2007) The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity. J Lipid Res 48:1637-1646
13. Gama CS, Salvador M, Andreazza AC, Kapczinski F, Silva B (2006) Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog Neuropsychopharmacol Biol Psychiatry 30:512-515
14. Haagen L, Brock A (1992) A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 30:391-395
15. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC (2005) Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 62(1):19-28
16. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD et al (2000) Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 20:2441-2447
17. Kawai H, Sakamoto F, Inoue Y (1990) Improved specific assay for serum arylesterase using a water-soluble substrate. Clin Chim Acta 188:177-182
18. Koncsos P, Seres I, Harangi M, Páll D, Józsa L, Bajnok L et al (2011) Favorable effect of short-term lifestyle intervention on human paraoxonase-1 activity and adipokine levels in childhood obesity. J Am Coll Nutr 30:333-339
19. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E et al (2001) Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 21(9):1451-1457
20. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M et al (2003) Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107:2775-2779
21. Miller NJ, Rice-Evans C (1996) Spectrophotometric determination of antioxidant activity. Redox Rep 2:161-171
22. Miller NJ, Johnston JD, Collis CS, Rice-Evans C (1997) Serum total antioxidant activity after myocardial infarction. Ann Clin Biochem 34:85-90
23. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW et al (1997) Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 99:2005-2019
24. Ozenoglu A, Balci H, Ugurlu S, Caglar E, Uzun H, Sarkis C et al (2008) The relationships of leptin, adiponectin levels and paraoxonase activity with metabolic and cardiovascular risk factors in females treated with psychiatric drugs. Clinics (Sao Paulo) 63:651-660
25. Paragh G, Asztalos L, Seres I, Balogh Z, Locsey L, Karpati I et al (1999) Serum paraoxonase activity changes in uremic and kidney-transplanted patients. Nephron 83:126-131
26. Pillai A, Parikh V, Terry AV, Mahadik SP (2007) Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 41:372-386
27. Precourt LP, Amre D, Denis MC, Lavoie JC, Delvin E, Seidman E et al (2011) The three-gene paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis 214:20-36
28. Rahman I, Swarskaa E, Henry M, Stolk I, MacNee W (2000) Is there any relationship between plasma antioxidant capacity and lung function in smokers and in patients with chronic obstructive pulmonary disease? Thorax 55:189-193
29. Rantala M, Silaste ML, Tuominen A, Kaikkonen J, Salonen JT, Alfthan G et al (2002) Dietary modifications and gene polymorphisms alter serum paraoxonase activity in healthy women. J Nutr 132:3012-3017
30. Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C (1999) Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med 26:1231-1237
31. Richter RJ, Jampsa RL, Jarvik GP, Costa LG, Furlong CE (2004) Determination of paraoxonase 1 status and genotypes at specific polymorphic sites. Curr Protoc Toxicol Chapter 4:Unit4
32. Ruetsch O, Viala A, Bardou H, Martin P, Vacheron MN (2005) Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management. Encéphale 31:507-516
33. Stefan Kropp S, Kern V, Lange K, Degner D, Hajak G, Kornhuber J et al (2005) Oxidative stress during treatment with first- and second-generation antipsychotics. J Neuropsychiatry Clin Neurosci 17:227-231
34. Ünsal C, Albayrak Y, Albayrak N, Kuloglu M, Hashimoto K (2013) Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine. Neuropsychiatr Dis Treat 9:1545-1552
35. Valabhji J, Mccoll AJ, Richmond W, Schachter M, Rubens MB, Elkeles RS (2001) Total antioxidant status and coronary artery calcification in type 1 diabetes. Diabetes Care 24:1608-1613
36. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK et al (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380:572-580
37. Walss-Bass C, Weintraub ST, Hatch J, Mintz J, Chaudhuri AR (2008) Clozapine causes oxidation of proteins involved in energy metabolism: a possible mechanism for antipsychotic-induced metabolic alterations. Int J Neuropsychopharmacol 11(8):1097-1104
38. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R et al (1990) SCAN. Schedules for clinical assessment in neuropsychiatry. Arch Gen Psychiatry 47:589-593
39. Winnier DA, Rainwater DL, Cole SA, Williams JT, Dyer TD, Blangero J et al (2007) Sex-specific QTL effects on variation in paraoxonase 1 (PON1) activity in Mexican Americans. Genet Epidemiol 31:66-74
40. Zhang XY, Tan YL, Cao LY, Wu GY, Xu Q, Shen Y et al (2006) Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 81:291-300
41. Zhang XY, Zhou DF, Shen YC, Zhang PY, Zhang WF, Liang J et al (2012) Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. Neuropharmacology 62(5-6):1928-1934
42. Zhang Y.,Chen M.,Chen J.,Wu Z.,Yu S.,Fang Y.,Zhang C., Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype,Psychopharmacology (Berlin), 2014, 231, 2211-2218, 1:CAS:528:DC%2BC2cXpvFWisA%3D%3D 10.1007/s00213-013-3410-4.